Previous 10 | Next 10 |
Integra LifeSciences Holdings Corporation (IART) Q4 2020 Earnings Conference Call February 18, 2021 08:30 ET Company Participants Mike Beaulieu - Director, Investor Relations Peter Arduini - President & Chief Executive Officer Carrie Anderson - Chief Financial Officer Glenn Coleman - Chie...
Image source: The Motley Fool. Integra Lifesciences Holdings Corp (NASDAQ: IART) Q4 2020 Earnings Call Feb 18, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Integra Lifesciences Holdings Corp (IART) Q4 2020 Earnin...
The following slide deck was published by Integra LifeSciences Holdings Corporation in conjunction with their 2020 Q4 earnings call. For further details see: Integra LifeSciences Holdings Corporation 2020 Q4 - Results - Earnings Call Presentation
Integra LifeSciences Holdings (IART): Q4 Non-GAAP EPS of $0.84 beats by $0.11; GAAP EPS of $1.09 beats by $0.79.Revenue of $388.64M (-1.6% Y/Y) beats by $2.66M.Press Release For further details see: Integra LifeSciences Holdings EPS beats by $0.11, beats on revenue
PRINCETON, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full-year ended December 31, 2020, consistent with its preliminary revenue results announced on January 14, 2021. ...
Integra LifeSciences ([[IART]] +2.4%) announces that it has completed the previously-disclosed acquisition of regenerative medicine company ACell.Integra had agreed to acquire ACell, which has a product portfolio based on porcine urinary bladder matrix platf...
PRINCETON, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-disclosed acquisition of ACell, Inc. “Acquiring ACell and its proprietary Matri...
Integra LifeSciences (IART) sees Q4 revenue in the range of $387-389M vs. a consensus $389.04M.“We are pleased with our execution and performance during the fourth quarter, despite the challenges brought on by the pandemic,” said Peter Arduini, Integra’s president and chi...
PRINCETON, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2020 revenue results. Preliminary Fourth Quarter a...
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has completed its previously announced divestiture of its Extremity Orthopedics business to Smith+Nephew (LSE:SN, N...
News, Short Squeeze, Breakout and More Instantly...
Integra LifeSciences Holdings Corporation Company Name:
IART Stock Symbol:
NASDAQ Market:
2024-07-30 13:15:02 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for IART on July 30, 2024 11:36AM ET. The previous analyst recommendation was Market Outperform. IART was trading at $24.945 at issue of the analyst recommendation. The overall analyst ...
2024-07-30 10:00:08 ET Richard Newitter from Truist Financial issued a price target of $26.00 for IART on 2024-07-30 08:59:00. The adjusted price target was set to $26.00. At the time of the announcement, IART was trading at $24.59. The overall price target consensus is ...
2024-07-30 06:30:09 ET Citigroup analyst issues SELL recommendation for IART on July 30, 2024 03:24AM ET. The previous analyst recommendation was Neutral. IART was trading at $25.42 at issue of the analyst recommendation. The overall analyst consensus : SELL. Current...